Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer
NCT00994864
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
235
Enrollment
OTHER
Sponsor class
Conditions
Colon Cancer
Interventions
DRUG:
FOLFOX
Sponsor
Jules Bordet Institute